Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Filgrastim 4Ifosfamide 3Carboplatin 3Peripheral Blood Stem Cell Transplantation 2Immune Checkpoint Inhibitors 2Etoposide 2spartalizumab 1regorafenib 1perifosine 1pegfilgrastim 1pazopanib 1ivosidenib 1etoposide phosphate 1enasidenib 1drozitumab 1angiotensin I (1-7) 1alanosine 1abemaciclib 1Vincristine 1Trabectedin 1Topotecan 1Thiotepa 1Sunitinib 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Radiotherapy, Conformal 1Radiotherapy 1Radiosurgery 1Proton Therapy 1Pharmacogenomic Testing 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Chondrosarcoma × drozitumab × Clear all
NCT00543712 2022-12-13

A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)

Genentech, Inc.

Phase 2 Terminated
15 enrolled
Sarcoma

Chondrosarcoma, Sarcoma, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡